The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
received:
09
02
2022
accepted:
17
01
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
23
4
2024
Statut:
epublish
Résumé
The gut microbiota modulates response to hormonal treatments in prostate cancer (PCa) patients, but whether it influences PCa progression remains unknown. Here, we show a reduction in fecal microbiota alpha-diversity correlating with increase tumour burden in two distinct groups of hormonotherapy naïve PCa patients and three murine PCa models. Fecal microbiota transplantation (FMT) from patients with high PCa volume is sufficient to stimulate the growth of mouse PCa revealing the existence of a gut microbiome-cancer crosstalk. Analysis of gut microbial-related pathways in mice with aggressive PCa identifies three enzymes responsible for the metabolism of long-chain fatty acids (LCFA). Supplementation with LCFA omega-3 MAG-EPA is sufficient to reduce PCa growth in mice and cancer up-grading in pre-prostatectomy PCa patients correlating with a reduction of gut Ruminococcaceae in both and fecal butyrate levels in PCa patients. This suggests that the beneficial effect of omega-3 rich diet is mediated in part by modulating the crosstalk between gut microbes and their metabolites in men with PCa.
Identifiants
pubmed: 38654015
doi: 10.1038/s41467-024-45332-w
pii: 10.1038/s41467-024-45332-w
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Fatty Acids, Unsaturated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3431Subventions
Organisme : Canadian Cancer Society Research Institute (Société Canadienne du Cancer)
ID : 400345
Informations de copyright
© 2024. The Author(s).
Références
Golombos, D. M. et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 111, 122–128 (2018).
pubmed: 28888753
doi: 10.1016/j.urology.2017.08.039
Liss, M. A. et al. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur. Urol. 74, 575–582 (2018).
pubmed: 30007819
pmcid: 6716160
doi: 10.1016/j.eururo.2018.06.033
Porter, C. M., Shrestha, E., Peiffer, L. B. & Sfanos, K. S. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 21, 345–354 (2018).
pubmed: 29795140
doi: 10.1038/s41391-018-0041-1
Daisley, B. A. et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat. Commun. 11, 4822 (2020).
pubmed: 32973149
pmcid: 7515896
doi: 10.1038/s41467-020-18649-5
Sfanos, K. S. et al. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 21, 539–548 (2018).
pubmed: 29988102
pmcid: 6283851
doi: 10.1038/s41391-018-0061-x
Li, J. K. M. et al. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy. Prostate Cancer Prostatic Dis https://doi.org/10.1038/s41391-021-00360-1 (2021).
Pernigoni, N. et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374, 216–224 (2021).
pubmed: 34618582
doi: 10.1126/science.abf8403
Cani, P. D. Human gut microbiome: hopes, threats and promises. Gut 67, 1716–1725 (2018).
pubmed: 29934437
doi: 10.1136/gutjnl-2018-316723
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
pubmed: 29097494
doi: 10.1126/science.aan3706
Clinton, S. K., Giovannucci, E. L. & Hursting, S. D. The World Cancer Research Fund/American Institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J. Nutr. 150, 663–671 (2020).
pubmed: 31758189
doi: 10.1093/jn/nxz268
Richman, E. L. et al. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern Med 173, 1318–1326 (2013).
pubmed: 23752662
pmcid: 3935610
doi: 10.1001/jamainternmed.2013.6536
Martinez-Guryn, K. et al. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe 23, 458–469.e455 (2018).
pubmed: 29649441
pmcid: 5912695
doi: 10.1016/j.chom.2018.03.011
Semova, I. et al. Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. Cell Host Microbe 12, 277–288 (2012).
pubmed: 22980325
doi: 10.1016/j.chom.2012.08.003
Anhe, F. F. et al. Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity. Nat. Metab. 2, 233–242 (2020).
pubmed: 32694777
doi: 10.1038/s42255-020-0178-9
Chang, S. N. et al. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice. Prostate 74, 1266–1277 (2014).
pubmed: 25053105
doi: 10.1002/pros.22843
Labbé, D. P. et al. PTP1B deficiency enables the ability of a high-fat diet to drive the invasive character of PTEN-deficient prostate cancers. Cancer Res 76, 3130–3135 (2016).
pubmed: 27020859
pmcid: 4891239
doi: 10.1158/0008-5472.CAN-15-1501
Labbé, D. P. et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat. Commun. 10, 4358 (2019).
pubmed: 31554818
pmcid: 6761092
doi: 10.1038/s41467-019-12298-z
Gevariya, N. et al. Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. Prostate 79, 9–20 (2019).
pubmed: 30073695
doi: 10.1002/pros.23706
Li, J. et al. Dietary supplementation of alpha-linolenic acid induced conversion of n-3 LCPUFAs and reduced prostate cancer growth in a mouse model. Lipids Health Dis. 16, 136 (2017).
pubmed: 28697730
pmcid: 5505143
doi: 10.1186/s12944-017-0529-z
Berquin, I. M. et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Invest 117, 1866–1875 (2007).
pubmed: 17607361
pmcid: 1890998
doi: 10.1172/JCI31494
Robitaille, K. A phase IIb randomized placebo-controlled trial testing a long-chain omega-3 fatty acid MAG-EPA dietary supplement on prostate cancer proliferation. Commun. Med. 18, 64 (2023).
Morris, E. K. et al. Choosing and using diversity indices: insights for ecological applications from the German Biodiversity Exploratories. Ecol. Evol. 4, 3514–3524 (2014).
pubmed: 25478144
pmcid: 4224527
doi: 10.1002/ece3.1155
DeJong, T. A comparison of three diversity indices based on their components of richness and evenness. Oikos 26, 222–227 (1975).
doi: 10.2307/3543712
Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).
pubmed: 32209449
doi: 10.1016/S0140-6736(20)30314-7
Klingenberg, S. et al. (68)Ga-PSMA PET/CT for primary lymph node and distant metastasis nm staging of high-risk prostate cancer. J. Nucl. Med 62, 214–220 (2021).
pubmed: 32444374
doi: 10.2967/jnumed.120.245605
Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).
pubmed: 28059767
pmcid: 5367887
doi: 10.1126/science.aah4199
Labbé, D. P. et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin. Cancer Res 23, 7072–7083 (2017).
pubmed: 28899973
pmcid: 5690819
doi: 10.1158/1078-0432.CCR-17-0413
Nyquist, M. D. et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).
pubmed: 32460015
pmcid: 7453577
doi: 10.1016/j.celrep.2020.107669
Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur. Urol. 76, 89–97 (2019).
pubmed: 30553611
doi: 10.1016/j.eururo.2018.11.045
Langille, M. G. et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31, 814–821 (2013).
pubmed: 23975157
pmcid: 3819121
doi: 10.1038/nbt.2676
Moussa, H. et al. Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level. Nutrients 11, https://doi.org/10.3390/nu11071616 (2019).
Moreel, X. et al. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prev. Res (Philos.) 7, 766–776 (2014).
doi: 10.1158/1940-6207.CAPR-13-0349
Watt, M. J. et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med 11, https://doi.org/10.1126/scitranslmed.aau5758 (2019).
Pelser, C., Mondul, A. M., Hollenbeck, A. R. & Park, Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol. Biomark. Prev. 22, 697–707 (2013).
doi: 10.1158/1055-9965.EPI-12-1196-T
Bidu, C. et al. The transplantation of omega3 PUFA-altered gut microbiota of fat-1 mice to wild-type littermates prevents obesity and associated metabolic disorders. Diabetes 67, 1512–1523 (2018).
pubmed: 29793999
doi: 10.2337/db17-1488
Kaliannan, K., Wang, B., Li, X. Y., Kim, K. J. & Kang, J. X. A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Sci. Rep. 5, 11276 (2015).
pubmed: 26062993
pmcid: 4650612
doi: 10.1038/srep11276
Guertin, M. H. et al. Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial. BMC Cancer 18, 64 (2018).
pubmed: 29321047
pmcid: 5763552
doi: 10.1186/s12885-017-3979-9
Cooper, C. S. et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet 47, 367–372 (2015).
pubmed: 25730763
pmcid: 4380509
doi: 10.1038/ng.3221
Epstein, J. I., Amin, M. B., Reuter, V. E. & Humphrey, P. A. Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 41, e1–e7 (2017).
pubmed: 28177964
doi: 10.1097/PAS.0000000000000820
Epstein, J. I. et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244–252 (2016).
pubmed: 26492179
doi: 10.1097/PAS.0000000000000530
Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur. Urol. 69, 428–435 (2016).
pubmed: 26166626
doi: 10.1016/j.eururo.2015.06.046
Hennes, D. et al. The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. BJU Int 128, 45–51 (2021).
pubmed: 34310033
doi: 10.1111/bju.15556
De Nunzio, C. et al. The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. Eur. J. Surg. Oncol. 44, 835–839 (2018).
pubmed: 29395435
doi: 10.1016/j.ejso.2017.12.003
Corcoran, N. M. et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 108, E202–E210 (2011).
pubmed: 21443656
doi: 10.1111/j.1464-410X.2011.10119.x
Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol 19, 55–71 (2021).
pubmed: 32887946
doi: 10.1038/s41579-020-0433-9
Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).
pubmed: 32358520
pmcid: 7195489
doi: 10.1038/s41467-020-16079-x
Matsushita, M. et al. Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF-1 signaling. Cancer Res https://doi.org/10.1158/0008-5472.CAN-20-4090 (2021).
Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806.e712 (2019).
pubmed: 31398337
pmcid: 7288240
doi: 10.1016/j.cell.2019.07.008
Emami, N. & Diamandis, E. P. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Mol. Oncol. 1, 269–287 (2007).
pubmed: 19383303
pmcid: 5543873
doi: 10.1016/j.molonc.2007.09.003
Yamasaki, K. et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20, 2068–2080 (2006).
pubmed: 17012259
doi: 10.1096/fj.06-6075com
Edstrom, A. M. et al. The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins. J. Immunol. 181, 3413–3421 (2008).
pubmed: 18714013
doi: 10.4049/jimmunol.181.5.3413
Muytjens, C. M., Vasiliou, S. K., Oikonomopoulou, K., Prassas, I. & Diamandis, E. P. Putative functions of tissue kallikrein-related peptidases in vaginal fluid. Nat. Rev. Urol. 13, 596–607 (2016).
pubmed: 27603220
doi: 10.1038/nrurol.2016.161
Edstrom Hagerwall, A. M. et al. beta-Microseminoprotein endows post coital seminal plasma with potent candidacidal activity by a calcium- and pH-dependent mechanism. PLoS Pathog. 8, e1002625 (2012).
pubmed: 22496651
pmcid: 3320615
doi: 10.1371/journal.ppat.1002625
Heidler, S. et al. The correlation of prostate volume and prostate-specific antigen levels with positive bacterial prostate tissue cultures. Urology 115, 151–156 (2018).
pubmed: 29526510
doi: 10.1016/j.urology.2018.02.035
Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. & Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57, 3325–3330 (1997).
pubmed: 9269988
Fassarella, M. et al. Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate. Gut health Gut 70, 595–605 (2021).
pubmed: 33051190
Costea, P. I. et al. Enterotypes in the landscape of gut microbial community composition. Nat. Microbiol 3, 8–16 (2018).
pubmed: 29255284
doi: 10.1038/s41564-017-0072-8
Ericsson, A. C. et al. Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PLoS One 10, e0116704 (2015).
pubmed: 25675094
pmcid: 4326421
doi: 10.1371/journal.pone.0116704
Manzano, R. G., Catalan-Latorre, A. & Brugarolas, A. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer 21, 432 (2021).
pubmed: 33879103
pmcid: 8056512
doi: 10.1186/s12885-021-08078-y
Jin, X. et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-kappaB activation and PD-L1 expression. Mol. Cell 73, 22–35.e26 (2019).
pubmed: 30527665
doi: 10.1016/j.molcel.2018.10.034
Gevariya, N. et al. Omega-3 eicosapentaenoic acid reduces prostate tumor vascularity. Mol. Cancer Res. 19, 516–527 (2021).
pubmed: 33262291
doi: 10.1158/1541-7786.MCR-20-0316
Menni, C. et al. Omega-3 fatty acids correlate with gut microbiome diversity and production of N-carbamylglutamate in middle aged and elderly women. Sci. Rep. 7, 11079 (2017).
pubmed: 28894110
pmcid: 5593975
doi: 10.1038/s41598-017-10382-2
Suzuki, T. A. & Ley, R. E. The role of the microbiota in human genetic adaptation. Science 370, https://doi.org/10.1126/science.aaz6827 (2020).
Miyamoto, J. et al. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat. Commun. 10, 4007 (2019).
pubmed: 31488836
pmcid: 6728375
doi: 10.1038/s41467-019-11978-0
Watson, H. et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut 67, 1974–1983 (2018).
pubmed: 28951525
doi: 10.1136/gutjnl-2017-314968
Vijay, A., Astbury, S., Le Roy, C., Spector, T. D. & Valdes, A. M. The prebiotic effects of omega-3 fatty acid supplementation: a six-week randomised intervention trial. Gut Microbes 13, 1–11 (2021).
pubmed: 33382352
doi: 10.1080/19490976.2020.1863133
Ribeiro-Vidal, H. et al. Antimicrobial Activity of EPA and DHA against Oral Pathogenic Bacteria Using an In Vitro Multi-Species Subgingival Biofilm Model. Nutrients 12, https://doi.org/10.3390/nu12092812 (2020).
Coraca-Huber, D. C., Steixner, S., Wurm, A. & Nogler, M. Antibacterial and anti-biofilm activity of Omega-3 polyunsaturated fatty acids against periprosthetic joint infections-isolated multi-drug resistant strains. Biomedicines 9, https://doi.org/10.3390/biomedicines9040334 (2021).
Motta, J. P., Wallace, J. L., Buret, A. G., Deraison, C. & Vergnolle, N. Gastrointestinal biofilms in health and disease. Nat. Rev. Gastroenterol. Hepatol. 18, 314–334 (2021).
pubmed: 33510461
doi: 10.1038/s41575-020-00397-y
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
pubmed: 29097493
doi: 10.1126/science.aan4236
Akrami, M. et al. Circulation of gut-preactivated naive CD8(+) T cells enhances antitumor immunity in B cell-defective mice. Proc. Natl Acad. Sci. USA 117, 23674–23683 (2020).
pubmed: 32907933
pmcid: 7519229
doi: 10.1073/pnas.2010981117
Schluter, J. et al. An association between the gut microbiota and immune cell dynamics in humans. BioRxiv https://doi.org/10.1101/618256 (2020).
Louis, P., Hold, G. L. & Flint, H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol 12, 661–672 (2014).
pubmed: 25198138
doi: 10.1038/nrmicro3344
Irrazabal, T., Belcheva, A., Girardin, S. E., Martin, A. & Philpott, D. J. The multifaceted role of the intestinal microbiota in colon cancer. Mol. Cell 54, 309–320 (2014).
pubmed: 24766895
doi: 10.1016/j.molcel.2014.03.039
Okumura, S. et al. Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion. Nat. Commun. 12, 5674 (2021).
pubmed: 34584098
pmcid: 8479117
doi: 10.1038/s41467-021-25965-x
Davidsson, S. et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod. Pathol. 26, 448–455 (2013).
pubmed: 23041830
doi: 10.1038/modpathol.2012.164
Flammiger, A. et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur. J. Cancer 49, 1273–1279 (2013).
pubmed: 23266046
doi: 10.1016/j.ejca.2012.11.035
Anhe, F. F. et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 64, 872–883 (2015).
pubmed: 25080446
doi: 10.1136/gutjnl-2014-307142
Chong, J., Liu, P., Zhou, G. & Xia, J. Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat. Protoc. 15, 799–821 (2020).
pubmed: 31942082
doi: 10.1038/s41596-019-0264-1
Parks, D. H., Tyson, G. W., Hugenholtz, P. & Beiko, R. G. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics 30, 3123–3124 (2014).
pubmed: 25061070
pmcid: 4609014
doi: 10.1093/bioinformatics/btu494